A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Details

Ressource 1Download: 1-s2.0-S0042682217301095-main.pdf (2334.92 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_38561B71F7B3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
Journal
Virology
Author(s)
Meador L.R., Kessans S.A., Kilbourne J., Kibler K.V., Pantaleo G., Roderiguez M.E., Blattman J.N., Jacobs B.L., Mor T.S.
ISSN
1096-0341 (Electronic)
ISSN-L
0042-6822
Publication state
Published
Issued date
07/2017
Peer-reviewed
Oui
Volume
507
Pages
242-256
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.

Pubmed
Web of science
Open Access
Yes
Create date
09/05/2017 17:30
Last modification date
20/08/2019 13:27
Usage data